(VIANEWS) – Kimball Electronics (KE), Extreme Networks (EXTR), Exelixis (EXEL) are the highest sales growth and return on equity stocks on this list.
Here is a list of stocks with an above 5% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?
1. Kimball Electronics (KE)
21.9% sales growth and 9.73% return on equity
Kimball Electronics, Inc. provides contract electronics manufacturing services and diversified manufacturing services to customers in the automotive, medical, industrial, and public safety end markets. The company's manufacturing services include design services and support, supply chain services and support, and rapid prototyping and product introduction support services, as well as product design, and process validation and qualification services. Its manufacturing services also comprise industrialization and automation of manufacturing processes; reliability testing, including testing of products under a series of environmental conditions; production and testing of printed circuit board assemblies; assembly, production, and packaging of medical disposables and other non-electronic products; design engineering and manufacturing of automation equipment, test and inspection equipment, and precision molded plastics; software design services; and product life cycle management services. The company has operations in the United States, China, Mexico, Poland, Romania, Thailand, and Vietnam. Kimball Electronics, Inc. was founded in 1961 and is headquartered in Jasper, Indiana.
Earnings Per Share
As for profitability, Kimball Electronics has a trailing twelve months EPS of $1.9.
PE Ratio
Kimball Electronics has a trailing twelve months price to earnings ratio of 14.36. Meaning, the purchaser of the share is investing $14.36 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 9.73%.
Earnings Before Interest, Taxes, Depreciation, and Amortization
Kimball Electronics’s EBITDA is 0.54.
Moving Average
Kimball Electronics’s value is way higher than its 50-day moving average of $22.81 and way higher than its 200-day moving average of $22.44.
Revenue Growth
Year-on-year quarterly revenue growth grew by 31.7%, now sitting on 1.7B for the twelve trailing months.
Yearly Top and Bottom Value
Kimball Electronics’s stock is valued at $27.29 at 11:22 EST, below its 52-week high of $28.18 and way higher than its 52-week low of $17.10.
2. Extreme Networks (EXTR)
20.9% sales growth and 57.35% return on equity
Extreme Networks, Inc. provides software-driven networking solutions worldwide. It designs, develops, and manufactures wired and wireless network infrastructure equipment; and develops software for network management, policy, analytics, security, and access controls. The company offers ExtremeCloud IQ, an ML/AI powered, wired, and wireless cloud network management solution that offers advanced visibility and control over users, devices, and applications; ExtremeCloud IQ – Site Engine that provides task automation, access control, granular visibility with real-time analytics and multi-vendor device management; and ExtremeCloud IQ Essentials offers WIPS, location services, IoT, and guest management services. It also provides wireless access point products; ExtremeSwitching portfolio that includes access edge products that offer physical presentations along with options to deliver Ethernet or convergence-friendly Power-over-Ethernet (POE), including high-power universal POE; aggregation/core switches designed to address aggregation, top-of-rack, and campus core environments; and data center switches and routers. In addition, the company offers cloud native platforms and applications for service providers; and customer support and services. It markets and sells its products through distributors, resellers, and field sales organizations to healthcare, education, government, manufacturing, retail, and hospitality markets. Extreme Networks, Inc. was incorporated in 1996 and is headquartered in Morrisville, North Carolina.
Earnings Per Share
As for profitability, Extreme Networks has a trailing twelve months EPS of $0.44.
PE Ratio
Extreme Networks has a trailing twelve months price to earnings ratio of 54.7. Meaning, the purchaser of the share is investing $54.7 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 57.35%.
Yearly Top and Bottom Value
Extreme Networks’s stock is valued at $24.07 at 11:22 EST, below its 52-week high of $24.40 and way higher than its 52-week low of $8.49.
Volume
Today’s last reported volume for Extreme Networks is 3484650 which is 112.88% above its average volume of 1636880.
Revenue Growth
Year-on-year quarterly revenue growth grew by 16.5%, now sitting on 1.23B for the twelve trailing months.
3. Exelixis (EXEL)
14% sales growth and 6.34% return on equity
Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of patients with progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors. The company also offers COTELLIC, an inhibitor of MEK as a combination regimen to treat advanced melanoma; and MINNEBRO, an oral non-steroidal selective blocker of the mineralocorticoid receptor for the treatment of hypertension in Japan. In addition, it is developing XL092, an oral tyrosine kinase inhibitor that targets VEGF receptors, MET, AXL, MER, and other kinases implicated in growth and spread of cancer; XB002, an antibody-drug conjugate composed of human mAb against tissue factor (TF) for the treatment of advanced solid tumors; XL102, an orally bioavailable cyclin-dependent kinase 7 (CDK7) inhibitor for the treatment of advanced or metastatic solid tumors; and XB002 for the treatment of non-hodgkin's lymphoma. Exelixis, Inc. has research collaborations and license agreements with Ipsen Pharma SAS; Takeda Pharmaceutical Company Ltd.; F. Hoffmann-La Roche Ltd.; Redwood Bioscience, Inc.; R.P. Scherer Technologies, LLC; Catalent Pharma Solutions, Inc.; NBE Therapeutics AG; Aurigene Discovery Technologies Limited; Iconic Therapeutics, Inc.; Invenra, Inc.; StemSynergy Therapeutics, Inc.; Genentech, Inc.; Bristol-Myers Squibb Company; and Daiichi Sankyo Company, Limited. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was incorporated in 1994 and is headquartered in Alameda, California.
Earnings Per Share
As for profitability, Exelixis has a trailing twelve months EPS of $0.47.
PE Ratio
Exelixis has a trailing twelve months price to earnings ratio of 40.62. Meaning, the purchaser of the share is investing $40.62 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 6.34%.
Earnings Before Interest, Taxes, Depreciation, and Amortization
Exelixis’s EBITDA is 3.08.
Growth Estimates Quarters
The company’s growth estimates for the present quarter and the next is a negative 31.8% and a negative 26.1%, respectively.
Revenue Growth
Year-on-year quarterly revenue growth grew by 14.8%, now sitting on 1.66B for the twelve trailing months.
Moving Average
Exelixis’s value is under its 50-day moving average of $19.29 and above its 200-day moving average of $17.50.
4. AMETEK (AME)
10.7% sales growth and 16.24% return on equity
AMETEK, Inc. manufactures and sells electronic instruments and electromechanical devices in North America, Europe, Asia, and South America. It operates in two segments, Electronic Instruments (EIG) and Electromechanical (EMG). The company's EIG segment offers advanced instruments for the process, aerospace, power, and industrial markets; process and analytical instruments for the oil and gas, petrochemical, pharmaceutical, semiconductor, automation, and food and beverage industries; and instruments to the laboratory equipment, ultra-precision manufacturing, medical, and test and measurement markets.Its EMG segment offers engineered electrical connectors and electronics packaging to protect sensitive devices and mission-critical electronics; precision motion control products for data storage, medical devices, business equipment, automation, and other applications; high-purity powdered metals, strips and foils, specialty clad metals, and metal matrix composites; motor-blower systems and heat exchangers for use in thermal management, military, commercial aircraft, and military ground vehicles; and motors for use in commercial appliances, fitness equipment, food and beverage machines, hydraulic pumps, and industrial blowers. This segment also operates a network of aviation maintenance, repair, and overhaul facilities. In addition, the company offers clinical and educational communication solutions. AMETEK, Inc. was incorporated in 1930 and is headquartered in Berwyn, Pennsylvania.
Earnings Per Share
As for profitability, AMETEK has a trailing twelve months EPS of $5.19.
PE Ratio
AMETEK has a trailing twelve months price to earnings ratio of 31.17. Meaning, the purchaser of the share is investing $31.17 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 16.24%.
Volume
Today’s last reported volume for AMETEK is 192204 which is 80.74% below its average volume of 998314.
Moving Average
AMETEK’s worth is way higher than its 50-day moving average of $145.82 and way higher than its 200-day moving average of $137.80.
Growth Estimates Quarters
The company’s growth estimates for the current quarter and the next is 9.4% and 5.5%, respectively.
Previous days news about AMETEK(AME)
- According to Zacks on Wednesday, 28 June, "Some better-ranked stocks in the broader technology sector are Palo Alto Networks (PANW Quick QuotePANW – Free Report) , Akamai Technologies (AKAM Quick QuoteAKAM – Free Report) and AMETEK (AME Quick QuoteAME – Free Report) . ", "Palo Alto Networks and Akamai Technologies sport a Zacks Rank #1 (Strong Buy), while AMETEK carries a Zacks Rank #2 (Buy) each. "
